|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acquired resistance to cancer drugs is common, also for modern targeted drugs like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, a new drug approved for the treatment of the highly aggressive and relapsing mantle cell lymphoma (MCL).
|
29483220 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mantle cell lymphoma (MCL) is characterized by increased B-cell receptor (BCR) signaling, and BTK inhibition is an effective therapeutic intervention in MCL patients.
|
29615403 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite the development of the novel Bruton tyrosine kinase inhibitor ibrutinib, mantle cell lymphoma (MCL) remains an incurable B-cell non-Hodgkin lymphoma.
|
29983879 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of B-cell receptor (BCR) signaling through the BTK inhibitor, ibrutinib, has generated a remarkable response in mantle cell lymphoma (MCL).
|
30510142 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of BTK inhibitors in treating MCL will evolve substantially over the coming years as results from a number of trials become available, particularly in relation to potential upfront use and possible synergy with other targeted therapies such as B-cell lymphoma 2, phosphoinositide 3-kinase and checkpoint inhibitors.
|
30052472 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bruton tyrosine kinase is a clinically validated target in mantle cell lymphoma.
|
29241979 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Promising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma.
|
29392403 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both the BTK inhibitor ibrutinib and the BCL2 inhibitor venetoclax are active as monotherapy in the treatment of mantle-cell lymphoma.
|
29590547 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, simultaneous suppression of BTK and mTOR may be indicated as a potential therapeutic modality for the treatment of MCL.
|
28905990 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Understanding resistance mechanisms to BTK and BCL2 inhibitors in mantle cell lymphoma: implications for design of clinical trials.
|
29912596 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL).
|
30115641 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert commentary: BTK inhibitors have demonstrated efficacy in patients with relapsed or refractory MCL.
|
29737219 |
2018 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several second generation BTK inhibitors are in clinical development and might further improve tolerability and efficacy of therapy in advanced stage CLL and MCL.
|
28661188 |
2017 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, an oral Bruton tyrosine kinase inhibitor, has demonstrated efficacy and CNS penetration in relapsed or refractory MCL with rapid and complete response even after 1 year of follow-up.
|
28063897 |
2017 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, α-BCR-induced signaling strength was variable across patient samples and correlated with BCR subunit CD79B expression, but was inversely correlated with susceptibility to Bruton tyrosine kinase (BTK) and SYK inhibitors in MCL.
|
28011673 |
2017 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two agents are already approved in the USA and Europe: ibrutinib, a BTK inhibitor, for the treatment of chronic lymphatic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström's macroglobulinemia; and idelalisib, a PI3Kδ inhibitor, for the treatment of CLL and follicular lymphoma.
|
28295729 |
2017 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a Bruton's tyrosine kinase inhibitor, is the newest drug in the arsenal that has shown promising efficacy in relapsed mantle cell lymphoma.
|
26970573 |
2017 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At the time of relapse, agents directed at activated pathways in MCL cells such as bortezomib (NFkB inhibitor), lenalidamide (anti-angiogenesis) and Ibruitinib (Bruton's Tyrosine Kinase [BTK] inhibitor) have demonstrated excellent clinical activity in MCL patients.
|
28699667 |
2017 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Introduction of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib has markedly improved MCL therapy outcome, but drug resistance remains a challenge.
|
29296874 |
2017 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
HSP90 inhibition induced the complete degradation of both BTK and IκB kinase α in MCL lines and CD40-dependent B cells, with downstream loss of MAPK and nonclassical NF-κB signaling.
|
27742706 |
2016 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
|
27157620 |
2016 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ibrutinib, a clinically approved irreversible BTK kinase inhibitor for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL) etc, has been reported to be potent against EGFR mutant kinase and currently being evaluated in clinic for Non Small Cell Lung Cancer (NSCLC).
|
27626175 |
2016 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, the Bruton tyrosine kinase (BTK) inhibitor ibrutinib demonstrated important clinical activity in MCL.
|
27127301 |
2016 |
|
Mantle cell lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeting the HDACs by using either RNA interference against HDAC1 in CLL or a small molecule inhibitor (HDACi) in CLL and mantle cell lymphoma restored the expression of the BTK-targeting miRs with loss of BTK protein and downstream signaling and consequent cell death.
|
27756747 |
2016 |
|
Mantle cell lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strong synergism was observed with pimasertib combined with the PI3K inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma.
|
26961147 |
2016 |